Inadequate control of lipid levels in patients with a previous myocardial infarction

New Zealand Medical Journal

Volumn 111, Issue 1079, 1998, Pages 464-467

  Ellis, Christopher J ^a   Zambanini, Andrew ^b   French, John K ^b   Denton, Mary ^b   Johnson, Roger ^c   Patel, Hitesh ^d   White, Harvey D ^e  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b Green Lane Hospital

^c NATIONAL WOMEN S HOSPITAL   (New Zealand)

^d TAURANGA HOSPITAL   (New Zealand)

^e GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DIET; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE;

AGED; CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; TRIGLYCERIDES;

EID: 0032509077     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
2. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
3. Sacks KM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
4. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992; 304: 431-40.
5. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand Guidelines for detection and management of dyslipidaemia. NZ Med J 1993; 106: 133-42.
6. Ellis CJ, French JK, White HD et al. Results of percutaneous coronary angioplasy in patients < 40 years of age. Am J Cardiol. 1998; 82: 135-9.
7. French JK, Scott DS, Whitlock RML et al. Late outcome after coronary artery bypass graft surgery in patients < 40 years old. Circulation 1995; 92 Suppl II: 11-14-11-19.
8. The ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease : ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-42.
9. White HD, Norris RM, Brown MA et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317: 850-5.
10. White HD, Rivers JJ, Maslowski AH et al. Effect of intravenous streptokinase as compared to that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med 1989; 320: 817-21.
11. French JK, Amos DJ, Williams BF et al. Effects of early captopril administration following thrombolysis on regional wall motion in relation to infarct artery flow. J Am Coll Cardiol: In press 1998.
12. French JK, Williams BF, Hart HH et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ 1996; 312: 1637-41.
13. Rivers JT, White HD, Cross DB et al. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management incidence and effect of smoking. J Am Coll Cardiol 1990; 16: 340-8.
14. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882-4.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
16. Jackson R, White H, Marshall R et al. Changes in serum lipid concentrations during first 24 hours after myocardial infarction. BMJ 1987; 294: 1588-9.
17. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. NZ Med J 1996; 109: 224-32.
18. Pedersen TR, Kjekshus J, Berg K et al. Cholesterol lowering and the use of healthcare resources : results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1796-802.
19. Jonsson B, Johannesson M, Kjekshus J et al. Cost effectiveness of cholesterol lowering results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17: 1001-7.
20. Johannesson M, Jonsson B, Kjekshus J et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-6.
21. Campeau L, Enjalbert M, Lespérance J et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation : a study ten years after aorto-coronary bypass surgery. N Engl J Med 1984; 311: 1329-32.
22. Blankenhorn DH, Nessim SA, Johnson RL et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40.
23. The Post Coronary Artery Bypass Grafting Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl J Med 1997; 336: 153-62.
24. Ketley D, Woods KL. Impact of clinical trials on clinical practice : example of thrombolvsis for acute myocardial infarction. Lancet 1993; 342: 891-4.
25. Patel H, Neutze JM, Kerr B, White HD. Failure of implementation of the National Heart Foundation of New Zealand Guidelines for the management of dyslipidaemia. NZ Med J 1996; 109: 24-6.
26. Pharmaceutical Management Agency Ltd (PHARMAC). New Zealand Pharmaceutical Schedule - December 1996. Wellington.
27. Pharmaceutical Management Agency Ltd (PHARMAC). New Zealand Pharmaceutical Schedule - August 1997. Wellington.
28. Ose L, Scott R. Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia. Clin Drug Invest 1995; 10: 127-38.
29. Ellis CJ, Elliott J, Wilkins G, McHaffie D. Statins and Pharmac [letter]. NZ Med J 1998; 111: 38.
30. Jones P, Kafonek S, Laurora I, Hunninghale D, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvostatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81: 582-7.